Valiant Laboratories FY26: revenue ₹217 cr, loss ₹3.27 cr

Share price snapshot (Aug 2026)

Valiant Laboratories’ share price was reported at ₹64.6 as of 8 August 2026. On 7 August 2026, the stock was cited at ₹64.59 on NSE and ₹65.1 on BSE. These levels come as the company prepares to take up periodic financial reporting through scheduled board meetings and exchange filings. For investors tracking smaller chemical and pharma-linked manufacturers, the combination of audited annual numbers and upcoming quarterly results often shapes near-term sentiment. The data points in this update are drawn from company announcements and reported financial summaries referenced in the provided text.

What the company disclosed on FY26 audited results

Valiant Laboratories Limited published its audited standalone and consolidated financial results for the quarter and year ended March 31, 2026 in newspapers Financial Express (English) and Mumbai Lakshadeep (Marathi) on May 16, 2026. The disclosure was stated to be in compliance with Regulation 30 and Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on May 14, 2026 in Mumbai. The company also noted that its statutory auditors, Raman S. Shah & Co., issued an unmodified opinion on both standalone and consolidated financial results.

Standalone FY26: profit returns, revenue rises

On a standalone basis for FY26, Valiant Laboratories reported revenue from operations of ₹217.04 crore (₹21,704.25 lakhs). Standalone net profit for FY26 was ₹5.55 crore (₹554.82 lakhs), compared with a net loss of ₹2.15 crore (₹215.02 lakhs) in FY25. The company also reported that the standalone results reflected a pre-tax profit of ₹7.55 crore (₹754.79 lakhs) for FY26, versus a pre-tax loss of ₹1.45 crore (₹144.78 lakhs) in FY25. The improvement was attributed in the provided text to the chemical manufacturing business.

Consolidated FY26: higher subsidiary costs weigh

On a consolidated basis, which includes subsidiary Valiant Advanced Sciences Private Limited, the group reported a net loss of ₹3.27 crore (₹326.79 lakhs) for FY26. Consolidated revenue from operations was reported at ₹237.47 crore (₹23,746.75 lakhs). The consolidated narrative in the provided text highlighted that higher costs associated with the subsidiary’s operations offset the benefit of profitability in the March quarter. As a result, the full-year consolidated outcome remained negative despite the quarter-level profit.

March quarter (Q4 FY26): profit and sales jump

For the quarter ended March 31, 2026, standalone net profit was ₹3.53 crore (₹353.28 lakhs) on total income of ₹66.08 crore (₹6,607.61 lakhs). Separately, another reported financial summary stated that net profit rose 151.43% to ₹1.76 crore in the quarter ended March 2026, while sales rose 59.16% to ₹91.98 crore. The same summary also stated that for the full year ended March 2026, net loss was ₹3.27 crore versus ₹2.20 crore in the previous year, and sales rose to ₹237.47 crore from ₹133.38 crore. The text also includes another full-year summary line stating revenue reached ₹239.79 crore and profit touched ₹-3.27 crore, which is directionally consistent with a consolidated loss but differs from the ₹237.47 crore sales figure.

Q1 FY26 performance: turnaround from losses

For Q1 FY26, the company’s consolidated figures table (as cited) showed total income of ₹47.48 crore. This was up 43.5% quarter-on-quarter (from ₹33.09 crore in Q4 FY25) and up 118.8% year-on-year (from ₹21.70 crore in Q1 FY25). Total expenses in Q1 FY26 were ₹45.02 crore, up 26.2% QoQ and up 106.0% YoY. Profit before tax was ₹2.45 crore in Q1 FY26, compared with a loss of ₹2.57 crore in Q4 FY25 and a loss of ₹0.16 crore in Q1 FY25. Profit after tax was ₹1.82 crore in Q1 FY26 versus a loss of ₹1.24 crore in Q4 FY25 and a loss of ₹0.51 crore in Q1 FY25, with EPS at ₹0.40.

Q3 FY25 snapshot: revenue up QoQ, down YoY

For the quarter-ended December (Q3 FY25), Valiant Laboratories reported a 48.2% QoQ increase in consolidated revenues, while revenues declined 13.0% on a YoY basis. Expenses were up 22.4% QoQ and down 25.6% YoY. Net profit decreased 149.6% QoQ and decreased 167.1% YoY, as stated in the provided text. EPS for Q3 FY25 was reported at 0.5.

Key numbers at a glance

Corporate actions and compliance updates

The company’s exchange disclosure trail in the provided text includes multiple compliance updates. On 26 June 2026, Valiant Laboratories announced closure of its trading window. On 13 July 2026, it filed a compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. On 5 August 2026, the company issued a board meeting intimation for approval of financial results for the quarter ended June 30, 2026. Separately, an “Upcoming Events” line referenced quarterly results with an announcement date of Aug 10, 2026.

Auditor appointments for FY27

At its meeting on May 14, 2026, the Board reappointed Rajesh Chheda & Co. (FRN: 112887W) as Internal Auditor and Ketki D. Visariya & Co. (FRN: 000362) as Cost Auditor for FY 2026-27, effective May 14, 2026. Such appointments are typically watched for governance continuity, especially around periods when audited numbers and subsidiary performance are being assessed by the market.

Contact and registered communication details (as provided)

The address listed in the provided text was 104, Udyog Kshetra, Mulund Goregaon Link Road, Mulund West, Mumbai, Maharashtra 400080. The telephone number listed was 022-49712001. The compliance email cited was complianceofficer@valiantlabs.in. These details matter for investors who track official communication channels and statutory disclosures.

Why these disclosures matter for investors

The FY26 picture presented in the provided information is mixed: standalone profitability returned alongside higher revenues, while consolidated results stayed in loss due to higher costs linked to the subsidiary. That difference is important because market participants often evaluate cash generation and sustainability across the group, not only the parent entity. The scheduled board meeting for quarterly results also becomes a key checkpoint, given that the more recent quarterly trend (Q1 FY26) shows profitability after earlier losses. Separately, the presence of a stated tax demand notice of about ₹12.53 crore is a material item that investors typically watch for its potential impact on cash flows, although the provided text does not specify the period or resolution status.

Conclusion

Valiant Laboratories’ disclosures up to August 2026 show a recovery in standalone FY26 profitability, contrasted with a consolidated FY26 loss driven by higher subsidiary costs. With the stock cited around ₹65 and a board meeting scheduled to consider results for the quarter ended June 30, 2026, the next formal financial update is positioned as a near-term milestone in the company’s reporting calendar.